Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation
Heinz AT, Calkoen FG, Derbich A, Miltner L, Seitz C, Doering M, Braun C, Atar D, Schumm M, Heubach F, Arendt AM, Schulz A, Schuster FR, Meisel R, Strahm B, Finke J, Heineking B, Stetter S, Silling G, Stachel D, Gruhn B, Debatin KM, Foell J, Schulte JH, Woessmann W, Mauz-Körholz C, Tischer J, Feuchtinger T, Handgretinger R, Lang P (2023)
Publication Type: Journal article
Publication year: 2023
Journal
Book Volume: 108
Pages Range: 2080-2090
Journal Issue: 8
DOI: 10.3324/haematol.2022.281996
Abstract
Therapy-resistant viral reactivations contribute significantly to mortality after hematopoietic stem cell transplantation. Adoptive cellular therapy with virus-specific T cells (VST) has shown efficacy in various single-center trials. However, the scalability of this therapy is hampered by laborious production methods. In this study we describe the in-house production of VST in a closed system (CliniMACS Prodigy® system, Miltenyi Biotec). In addition, we report the efficacy in 26 patients with viral disease following hematopoietic stem cell transplantation in a retrospective analysis (adenovirus, n=7; cytomegalovirus, n=8; Epstein-Barr virus, n=4; multi-viral, n=7). The production of VST was successful in 100% of cases. The safety profile of VST therapy was favorable (n=2 grade 3 and n=1 grade 4 adverse events; all three were reversible). A response was seen in 20 of 26 patients (77%). Responding patients had a significantly better overall survival than patients who did not respond (P<0.001). Virus-specific symptoms were reduced or resolved in 47% of patients. The overall survival of the whole cohort was 28% after 6 months. This study shows the feasibility of automated VST production and safety of application. The scalability of the CliniMACS Prodigy® device increases the accessibility of VST treatment.
Authors with CRIS profile
Involved external institutions
Universitätsklinikum Tübingen
Germany (DE)
Princess Máxima Center
Netherlands (NL)
Universitätsklinikum Ulm
Germany (DE)
Heinrich-Heine-Universität Düsseldorf
Germany (DE)
Albert-Ludwigs-Universität Freiburg
Germany (DE)
Universitätsklinikum Freiburg
Germany (DE)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
Universitätsklinikum Regensburg
Germany (DE)
Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen
Germany (DE)
Universitätsklinikum Jena
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Justus-Liebig-Universität Gießen
Germany (DE)
Klinikum der Universität München
Germany (DE)
Abu Dhabi Stem Cell Center (ADSCC)
United Arab Emirates (AE)
Germany (DE)
Princess Máxima Center
Netherlands (NL)
Universitätsklinikum Ulm
Germany (DE)
Heinrich-Heine-Universität Düsseldorf
Germany (DE)
Albert-Ludwigs-Universität Freiburg
Germany (DE)
Universitätsklinikum Freiburg
Germany (DE)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
Universitätsklinikum Regensburg
Germany (DE)
Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen
Germany (DE)
Universitätsklinikum Jena
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Justus-Liebig-Universität Gießen
Germany (DE)
Klinikum der Universität München
Germany (DE)
Abu Dhabi Stem Cell Center (ADSCC)
United Arab Emirates (AE)
How to cite
APA:
Heinz, A.T., Calkoen, F.G., Derbich, A., Miltner, L., Seitz, C., Doering, M.,... Lang, P. (2023). Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation. Haematologica, 108(8), 2080-2090. https://doi.org/10.3324/haematol.2022.281996
MLA:
Heinz, Amadeus T., et al. "Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation." Haematologica 108.8 (2023): 2080-2090.
BibTeX: Download